XML 21 R54.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intangible Assets (Narrative) (Details) (USD $)
12 Months Ended 0 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Patents
Dec. 31, 2013
Product, Kristalose
Product and License Rights
Dec. 31, 2013
Collaborative Arrangement, Amended International Agreement
Dec. 31, 2011
Product Rights Agreement, U.S. Commercialization Rights for Kristalose from Inalco Biochemicals, Inc. and Inalco S.p.A.
Product, Kristalose
Product and License Rights
Oct. 29, 2013
Pernix Therapeutics
Collaborative Arrangement, Amended International Agreement
Oct. 29, 2013
Minimum
Pernix Therapeutics
Collaborative Arrangement, Amended International Agreement
Oct. 29, 2013
Maximum
Pernix Therapeutics
Collaborative Arrangement, Amended International Agreement
Acquired Finite-Lived Intangible Assets [Line Items]                    
Other revenue, potential upfront payment related to product sales           $ 4,000,000   $ 4,000,000    
Potential royalty payment, percentage of gross profit                 15.00% 20.00%
Product rights agreement, quarterly payments, expiration date             7 years      
Intangible assets, useful life         15 years          
Quarterly payments made             800,000      
Amortization of intangible assets 896,156 506,332 655,302              
Additions to intangible assets 7,462,080 2,071,926 180,269 2,100,000            
Amortization of intangible assets                    
2014 1,200,000                  
2015 1,200,000                  
2016 1,200,000                  
2017 1,200,000                  
2018 $ 1,200,000